The bottom line for the sector as a whole definitively improved last year; net losses were down by 30%, whereas revenue was up 18% ($60 billion). Although the European biotech sector swelled, with 23 initial public offerings last year, R&D spending in the region declined by more than one-fifth. Healthcare dominates biotech in the United States, whereas European biotech is more diverse in focus.
Source: Ernst & Young
Source: Ernst & Young
Source: Ernst & Young
Source: Ernst & Young
Source: Ernst & Young
Rights and permissions
About this article
Cite this article
Lawrence, S. State of biotech sector—2005. Nat Biotechnol 24, 603 (2006). https://doi.org/10.1038/nbt0606-603
Issue Date:
DOI: https://doi.org/10.1038/nbt0606-603
